





COMPASS Comprehensive Assay

a 1021 genes, targeted Next-Generation Sequencing (NGS) panel, designed to deliver personalized treatment decisions for multiple solid tumour types

Multiple Variant Types



*Clinical Validation ongoing



ICI: Immune checkpoint inhibitor
HRR: Homologous recombination repair
PARP: Poly adenosine diphosphate-ribose polymerase

Comprehensive

NGS of 1021 genes in a single test for treatment selection

Actionable

Validated for clinically actionable genes for multiple cancer types

Fast

Fast turnaround time for quick treatment decision

Sample Requirements



Provide 10 unstained sections (5-10 μm thick) on uncoated / uncharged slides*



Provide 1 matching H&E stained slide with tumour region marked out



Tumour cellularity: $\geq 30\%$
Tumour region: $\geq 25 \text{ mm}^2$

*Additional 5 sections are required if tumour region $< 25 \text{ mm}^2$

mirxes

TO KNOW. TO ACT.

For more information on how COMPASS can support personalized treatment decisions, contact us at:

Address:

30 Biopolis St, #09-05/06 Matrix,
Singapore 138671

Distributed by:

Parkway Laboratories
Contact to order:
Tel: 6933 0801 / 6248 5807
Email: sgapadmin@parkwaypantai.com